Analysis Group to Present Research at ISPE 2026
Event: 42nd International Society for Pharmacoepidemiology (ISPE) Annual Meeting Dates: 29 August–2 September 2026 Host: International Society for Pharmacoepidemiology (ISPE) Location: Milan, Italy
Analysis Group, a global leader in drug safety epidemiology and regulatory RWE, will co-moderate one podium presentation session and present five research posters at the 42nd International Society for Pharmacoepidemiology (ISPE) Annual Meeting.
On Monday, August 31, from 3:30 to 5:00 p.m. CEST, in the Gold Room, Vice President Marianne Cunnington will co-moderate podium session 2C, “How Do Exposed Pregnancies End?”
On Tuesday, September 1, from 11:30 a.m. to 1:00 p.m. CEST, during poster session B in the Exhibition South Hall, researchers from Analysis Group – including Managing Principals Maral DerSarkissian, Mei Sheng Duh, and Mihran Yenikomshian, and Vice Presidents Marianne Cunnington, Lynn Huynh, and Enrico Zanardo – will present the following posters:
- B-011: Clinical Characteristics and Treatment Patterns in Cisplatin-Eligible versus Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients with Intent for Resection: A Multi-Country Retrospective Chart Review in Europe
- B-054: Comparison of Patient Reported Outcomes in Interstitial Lung Disease with and without Pulmonary Hypertension: Interim Results from the PHINDER Study
- B-063: Real World Continuity of Care for Medicare Patients with Plaque Psoriasis Treated with Tildrakizumab and Other Treatment Classes
- B-249: More than Just Fit-for-Use Data: a Structured Framework to Support Real World Study Decision Making
On Wednesday, September 2, from 12:15 to 1:15 p.m. CEST, in the Exhibit Hall, Managing Principal Maral DerSarkissian will present a rare disease spotlight poster:
- SLC-033: Clinical Characteristics Associated with Pulmonary Hypertension among Patients with Interstitial Lung Disease: Interim Results from the PHINDER Study
Further details on the podium presentation session and posters are available in our 2026 ISPE Presentation Guide. Analysis Group is a proud gold sponsor of this meeting.
Associated People
Marianne Cunnington
Vice PresidentDr. Cunnington has over 20 years of experience as a pharmaceutical industry epidemiologist. She specializes in the generation of real-world evidence (RWE) in support of the development and lifecycle management of pharmaceutical and vaccine products, with particular focus on regulatory risk management strategies and product benefit risk assessments. Dr. Cunnington focuses on regulatory epidemiology with design and execution of real-world post-marketing safety studies, as well as real-world studies to support the approval of new products in the context of innovative regulatory pathways. Her research expertise includes design, negotiation, and execution of real-world components of risk management plans for multiple new product submission with regulators across multiple geographies (US, UK, Europe, Japan, South Korea), post approval safety studies in the EU, post-marketing requirement and commitment studies in the US, and pregnancy registries. Prior to joining Analysis Group, Dr. Cunnington held several senior epidemiology positions within Novartis and GlaxoSmithKline (GSK). At GSK, she chaired the peer review forum for all pharmaceutical real world evidence projects, provided epidemiological expertise for the GSK’s Global Safety Board and was a managing board member of the Innovative Medicines Initiative’s public-private partnership, building an integrated European real-world data network to monitor medication safety in pregnancy. Dr. Cunnington is currently an elected board member representing European industry and service providers for the International Society of Pharmacoepidemiology.